ArticleMolecular neurobiology2025
Disulfiram Prevents Blood-Brain Barrier Disruption in Epileptic Mice by Inhibiting Astrocyte Pyroptosis to Improve Seizure Activity.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuroinflammation and Graft Survival in Pluripotent Stem Cell-Derived Therapies for the Central Nervous System.Journal of neurochemistry · 2026Review
- Pyroptosis in epilepsy: from pathophysiological mechanisms to therapeutic strategies.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a prevalent neurological disorder whose pathogenesis is closely associated with blood-brain barrier (BBB) disruption. Emerging evidence suggests that astrocytic pyroptosis may play a pivotal role in BBB impairment. Based on this, we propose two central hypotheses: (1) seizure activity triggers astrocytic pyroptosis and exacerbates BBB damage; (2) pharmacological inhibition of pyroptosis can restore BBB integrity and alleviate epileptic symptoms. This study established a kainic acid-induced mouse model of epilepsy and an in vitro BBB model. Cell pyroptosis was induced using LPS and ATP. The expression of BBB and pyroptosis-related proteins was assessed through Western blotting, immunofluorescence, and RT-PCR. Additionally, a pyroptosis inhibitor, disulfiram (DSF), was used to inhibit pyroptosis, and the therapeutic effects on epilepsy were evaluated through behavioral experiments, electroencephalography, and electron microscopy. BBB damage and pyroptosis were observed in the hippocampal tissue of mice following seizures, with immunofluorescence results indicating the occurrence of pyroptosis in astrocytes. In vitro experiments demonstrated that astrocyte pyroptosis leads to the downregulation of tight junction proteins in endothelial cells. Inhibition of pyroptosis by DSF improved the integrity of the BBB and resulted in reduced severity of seizure activity and improved cognitive function in mice. This study reveals the role of astrocyte pyroptosis in seizure activity and the consequent BBB damage. DSF mitigates seizure severity and cognitive impairment by inhibiting astrocyte pyroptosis and improving BBB integrity, offering new insights and targets for epilepsy treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.